[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335200-105":59,"doc-detail-335200-en":122},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":115,"head_meta":117,"extra_data":119,"updated_unix":121},105,"en","ndr1-mediates-pd-l1-deubiquitination-to-promote-prostate-cancer-immune-escape-via-usp10-research-open-access","NDR1 mediates PD-L1 deubiquitination-to promote prostate cancer immune escape via USP10 - Research Open Access","","Prostate cancer (PCa) is among the most common male genitourinary malignancies, yet anti-PD-L1 checkpoint blockade shows poor efficacy in PCa despite benefits in other cancers. NDR1 is implicated in innate immunity, but its contribution to PCa tumor immunity and immunotherapy remains unclear. The study identifies a positive association between NDR1 and PD-L1 expression in PCa, where NDR1 suppresses CD8+ T-cell infiltration and function to drive immune escape. NDR1 inhibition enhances CD8+ T-cell activation and strengthens anti-PD-L1 therapeutic effects. Mechanistically, NDR1 inhibits USP10-mediated ubiquitination and PD-L1 degradation, thereby elevating PD-L1 levels and promoting immune escape, suggesting combined NDR1/PD-L1 blockade as a strategy to improve PCa immunotherapy.",{"@graph":69,"@context":114},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ndr1-mediates-pd-l1-deubiquitination-to-promote-prostate-cancer-immune-escape-via-usp10-research-open-access/335200/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ndr1-mediates-pd-l1-deubiquitination-to-promote-prostate-cancer-immune-escape-via-usp10-research-open-access/335200.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108],{"name":109,"@type":110,"acceptedAnswer":111},"What therapeutic strategy does the study suggest?","Question",{"text":112,"@type":113},"It suggests that combined NDR1/PD-L1 inhibition could boost prostate cancer immunotherapy effectiveness by targeting a specific PD-L1 regulatory mechanism behind immunotherapy failure.","Answer","https://schema.org",{"og:url":83,"og:type":116,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":118,"canonical":83},"index,follow",{"doc_id":120,"site_id":62},335200,1790167971,{"code":4,"msg":5,"data":123},{"doc_id":120,"user_id":124,"nickname":92,"user_avatar":125,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":131,"language":132,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":67,"update_tm":136,"read_time":36,"preview_page_count":4},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Fu etal. Cell Communication and Signaling (2024) 22:429  \n[https://doi.org/10.1186/s12964-024-01805-5](https://doi.org/10.1186/s12964-024-01805-5)  \nCell Communication and Signaling  \n RESEARCH Open Access  \nNDR1 mediates PD-L1 deubiquitinationto promote prostate cancer immune escape via USP10  \nMeiling Fu1†, Jinxin Li2†, Zuodong Xuan1†, Zeyuan Zheng1, Yankuo Liu1, Zeyi Zhang1, Jianzhong Zheng1, Min Zhong1, Bin Liu1, Yifan Du1, Lei Zhang3* and Huimin Sun1,4*  \nAbstract  \nProstate cancer (PCa) is one of the most common male genitourinary system malignancies. Despite the significant benefits of anti-PD-L1 immune checkpoint inhibitor therapy in other cancers, the reasons for its poor therapeutic efficacy in prostate cancer (PCa) remain unclear. NDR1 plays an important role in innate immunity, but its role in tumor immunity and immunotherapy has not been investigated. The role of NDR1 in the immune microenvironment of PCa and the related mechanisms are unknown. Here, we found a positive correlation between NDR1 and PD-L1 expression in PCa. NDR1 significantly inhibits CD8 + T cell infiltration and function, thereby promoting immune escape in prostate cancer. More importantly, NDR1 inhibition significantly enhanced CD8 + T cell activation, which enhanced the therapeutic effect of anti-PD-L1 . Mechanistic studies revealed that NDR1 inhibits ubiquitination-mediated PD-L1 degradation via the deubiquitinase USP10, upregulates PD-L1, and promotes PCa immune escape. Thus, our study suggests a unique PD-L1 regulatory mechanism underlying PCa immunotherapy failure. The significance of NDR1 in PCa immune escape and its mechanism of action were clarified, and combined NDR1/PD-L1 inhibition was suggested as an approach to boost PCa immunotherapy effectiveness.  \nKeywords Prostate cancer, NDR1/STK38, PD-L1, Immune escape, Immune checkpoint Blockade, Anti-PD-1 therapy  \n†Meiling Fu, Jinxin Li and Zuodong Xuan contributed equally to this work.  \n*Correspondence: Lei Zhang [Drzhanglei@xmu.edu.cn](Drzhanglei@xmu.edu.cn)[ ](Drzhanglei@xmu.edu.cn)Huimin Sun [hmsun@xah.xmu.edu.cn](hmsun@xah.xmu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/.)[.](http://creativecommons.org/licenses/by-nc-nd/4.0/.)  \nFu etal. Cell Communication and Signaling (2024) 22:429 Page 2 of 16  \nGraphical Abstract  \nIntroduction  \nProstate cancer (PCa) ranks as a frequently occurring malignant tumor within the male genitourinary system, holding the position of the second most prevalent cancer among men [1]. Surgery, radiotherapy and androgen deprivation therapy (ADT) are the mainstays of conventional PCa treatment [2], with ADT serving as the primary therapy for advanced PCa [3]. Prostate cancer patients ultimately failed ADT treatment due to drug resistance and developed metastatic castration resistant prostate cancer (mCRPC) [4]. Moreover, in vivo research suggests t","cbCailI0h2GAoMbj","https://ap.wps.com/l/cbCailI0h2GAoMbj","pdf",12985373,16,"English","# Abstract\n# Introduction\n## Current limitations of anti-PD-1/PD-L1 therapy in prostate cancer\n## Rationale for studying PD-L1 regulation\n## Background on NDR1 (STK38) in signaling and cancer","[{\"question\":\"What therapeutic strategy does the study suggest?\",\"answer\":\"It suggests that combined NDR1/PD-L1 inhibition could boost prostate cancer immunotherapy effectiveness by targeting a specific PD-L1 regulatory mechanism behind immunotherapy failure.\"}]","NDR1 mediates PD-L1 deubiquitination-to promote prostate cancer immune escape via USP10 - Research Open Access | PDF",1790010109]